+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

ELISpot and FluoroSpot Assay Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 4896097
  • Report
  • June 2020
  • Region: Global
  • 111 Pages
  • Mordor Intelligence

FEATURED COMPANIES

  • Abcam
  • Bio-Connect B.V.
  • Bio-Techne Corporation
  • Lophius Biosciences GmbH
  • Mabtech AB
  • Oxford Immunotec
The major factors attributing to the growth of the ELISpot and FluoroSpot assay market are the rising vaccine research to tackle the drug-resistant strains challenge, the growing global occurrence of chronic illnesses, and technological innovations in ELISpot and FluoroSpot analyzers and assay kits which is assessed to upsurge the market growth for ELISpot and FluoroSpot assay.

ELISpot is a crucial path to vaccine development for many illnesses, namely AIDS, tuberculosis, HIV, malaria, cancer, and flu. The ELISpot test is among the most widely utilized immunoassays in clinical studies to assess vaccine. This reputation was based mainly on the higher sensitivity of the sample, statistical read-out, and ease of use in both large screening and individual tests. In fact, the test can be used to assess both T-cell reactions and vaccine-specific antibody-producing B cells.

Key Market Trends

Assay Kits is Expected to Hold the Largest Market Share in the ELISpot and FluoroSpot Assay Market

Dominant share is retained by the assay kits segment owing to the factors such as a high incidence of chronic ailments and increased use of these products for vaccine development in clinical studies.

As per the (WHO) World Health Organization, the main chronic illnesses presently make up nearly 60% of all fatalities and 43% of the worldwide disease burden. Their contribution is projected to increase up to 73% of all fatalities by 2020 and 60% of the worldwide morbidity. In addition, in developing countries, 79 percent of the deaths take place owing to chronic diseases. Furthermore, the technological innovation of assay kits and analyzers for ELISpot and FluoroSpot is also expected to drive the market growth.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall ELISpot and FluoroSpot assay market, throughout the forecast period. This is owing to factors such as the rising prevalence of chronic disorders such as infectious diseases and the geriatric population.

An estimated 45 percent or about 33 million Americans were diagnosed with at least one chronic disease, according to the National Center for Biotechnology Information (NCBI), which is further expected to upsurge the demand of ELISpot and FluoroSpot assay in coming years.

Competitive Landscape

The ELISpot and FluoroSpot assay market is moderately competitive and consists of a few major players. In terms of market share, few of the major players are currently dominating the market. And some prominent players are vigorously making acquisitions and new product launches with the other companies to consolidate their market positions across the globe.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support


This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abcam
  • Bio-Connect B.V.
  • Bio-Techne Corporation
  • Lophius Biosciences GmbH
  • Mabtech AB
  • Oxford Immunotec

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Chronic Diseases
4.2.2 Technological Breakthroughs in Test Kits and analyzers for ELISpot and FluoroSpot
4.3 Market Restraints
4.3.1 Availability of alternative detection technologies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Analyzers
5.1.2 Assay kits
5.1.3 Ancillary Products
5.2 By End User
5.2.1 Hospitals & Clinical labs
5.2.2 Biopharmaceutical Company
5.2.3 Research Institutes
5.3 By Application
5.3.1 Research
5.3.1.1 Vaccine Development
5.3.1.2 Clinical Trials
5.3.1.3 Cancer Research
5.3.2 Diagnostics
5.3.2.1 Infectious Disease
5.3.2.2 Transplants
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Becton, Dickinson and Company
6.1.2 U-Cytech Biosciences
6.1.3 Cellular Technologies Limited
6.1.4 Mabtech AB
6.1.5 Abcam
6.1.6 Autoimmun Diagnostika GmbH
6.1.7 Lophius Biosciences GmbH
6.1.8 Bio-Connect B.V.
6.1.9 Oxford Immunotec
6.1.10 Bio-Techne Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Becton, Dickinson and Company
  • U-Cytech Biosciences
  • Cellular Technologies Limited
  • Mabtech AB
  • Abcam
  • Autoimmun Diagnostika GmbH
  • Lophius Biosciences GmbH
  • Bio-Connect B.V.
  • Oxford Immunotec
  • Bio-Techne Corporation
Note: Product cover images may vary from those shown

Loading
LOADING...